Original article
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study
Persistencia al tratamiento a largo plazo y reducción mantenida de los niveles de colesterol LDL con evolocumab durante 30 meses: resultados de la cohorte española del estudio prospectivo europeo HEYMANS
Agustín Blanco Echevarríaa,b,
, Juan De Dios García Díazc, Assumpta Caixasd,e, Núria Plana Gilf,g, Miguel Ángel Rico Corralh, Ian Bridgesi, Nafeesa Dhalwanij, Sònia Gatell Menchenk, Kausik K. Rayl
Corresponding author
a Internal Medicine Department, University Hospital October 12, i+12 Institute, Madrid, Spain
b Department of Medicine, Complutense University of Madrid, Madrid, Spain
c Internal Medicine Department, Prince of Asturias University Hospital, Madrid, Spain
d Endocrinology and Nutrition Department, Parc Taulí University Hospital, Parc Taulí Research and Innovation Institute (I3PT), Sabadell, Spain
e Medicine Department, Autonomous University of Barcelona, Sabadell, Spain
f Vascular Medicine and Metabolism Unit, IISPV, University Hospital Sant Joan de Reus, Reus, Spain
g Department of Medicine and Surgery, Rovira i Virgili University, CIBERDEM, Reus, Spain
h Internal Medicine Department, Virgen de la Macarena Hospital, Sevilla, Spain
i Amgen Ltd, Uxbridge, UK
j Amgen Inc., Thousand Oaks, CA, USA
k Amgen SA, Barcelona, Spain
l Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, UK
Ver másRead
225
Timeswas read the article
61
Total PDF
164
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 13 | 9 | 22 |
| 2024 October | 27 | 12 | 39 |
| 2024 September | 44 | 9 | 53 |
| 2024 August | 22 | 4 | 26 |
| 2024 July | 13 | 5 | 18 |
| 2024 June | 23 | 7 | 30 |
| 2024 May | 17 | 14 | 31 |
| 2024 April | 5 | 1 | 6 |